4,901 trials
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 2300 ng·h/mL
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 1719 ng·h/mL
Healthy Volunteer · Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants…
Healthy
Primary: Absolute Bioavailability Of Ravulizumab Subcutaneous (SC)/rHuPH20 — 64; 73; 77; 84 Percent bioavailability
Peanut Allergic Subjects
Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Sotorasib — 7160; 4850 ng/mL
Healthy Adult Subjects
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and…
Healthy · Type 2 Diabetes Mellitus (T2DM)
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) — 0; 0; 0; 0 Participants
Relapsed, Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Number of Participants With DLTs to Determine the MTD — 0; 0; 0; 1 Participants
Healthy
Primary: Two-way Crossover Period: Maximum Observed Concentration (Cmax) For Plasma Total Molybdenum (Mo) — 227.0186; 238.2725 nanograms (ng)/milliliter (mL)
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A — 2.45; 1.84 Units on a Scale
Healthy Volunteers
Primary: Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site — 8; 8; 8; 4 Participants
Duchenne and Becker Muscular Dystrophy · Polycytemia Vera
Primary: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF) — 1.0; 0.5; 10.2; 0.3 Milliseconds (msec)
Viral Respiratory Tract Infection
Primary: Part A Treatment Emergent Adverse Events — 4; 3; 2; 3 Participants
Amyotrophic Lateral Sclerosis
Primary: Percent Change in HERV-K Level — -30.7 Percent change